We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEO icon
426
NeoGenomics
NEO
$1.99B
$140K ﹤0.01%
9,486
-25,184
-73% -$394K
ATXS
427
DELISTED
Astria Therapeutics
ATXS
$134K ﹤0.01%
+12,153
New +$135K
CTKB icon
428
Cytek Biosciences
CTKB
$566M
$97.4K ﹤0.01%
17,586
-138,173
-89% -$784K
CFFN icon
429
Capitol Federal Financial
CFFN
$1.09B
$76.9K ﹤0.01%
+13,165
New +$77.5K
BFLY.WS
430
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$60.1K ﹤0.01%
733,333
– –
NXDR
431
Nextdoor Holdings
NXDR
$885M
$51.1K ﹤0.01%
+20,586
New +$52.9K
OPK icon
432
Opko Health
OPK
$1.02B
$34K ﹤0.01%
+22,796
New +$33.8K
QSIAW
433
DELISTED
Quantum-Si Inc Warrant
QSIAW
$29.1K ﹤0.01%
333,333
– –
TOIIW
434
The Oncology Institute Warrant
TOIIW
$4.35M
$25K ﹤0.01%
1,250,000
– –
NUVB.WS
435
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$16.3K ﹤0.01%
166,666
– –
CMAXW
436
DELISTED
CareMax, Inc. Warrant
CMAXW
$6.65K ﹤0.01%
672,000
– –
SRZNW icon
437
Surrozen Inc Warrant
SRZNW
$36.6K
$1.72K ﹤0.01%
166,666
– –
ABT icon
438
Abbott
ABT
$188B
– –
-4,101
Closed -$426K
ADPT icon
439
Adaptive Biotechnologies
ADPT
$3.61B
– –
-122,841
Closed -$445K
ADUS icon
440
Addus HomeCare
ADUS
$2.22B
– –
-2,407
Closed -$279K
AGYS icon
441
Agilysys
AGYS
$3.21B
– –
-8,752
Closed -$911K
AIG icon
442
American International
AIG
$42.5B
– –
-5,562
Closed -$413K
AKRO
443
DELISTED
Akero Therapeutics
AKRO
– –
-11,867
Closed -$278K
ALTG icon
444
Alta Equipment Group
ALTG
$194M
– –
-16,909
Closed -$136K
OSG
445
Octave Specialty Group
OSG
$257M
– –
-89,619
Closed -$1.15M
AME icon
446
Ametek
AME
$53.9B
– –
-3,011
Closed -$502K
AMPH icon
447
Amphastar Pharmaceuticals
AMPH
$907M
– –
-6,623
Closed -$265K
AN icon
448
AutoNation
AN
$7.7B
– –
-3,204
Closed -$511K
ANGO icon
449
AngioDynamics
ANGO
$605M
– –
-109,536
Closed -$663K
ANIP icon
450
ANI Pharmaceuticals
ANIP
$1.86B
– –
-5,138
Closed -$327K
16 17
18
19 20

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.